Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine – New England Journal of Medicine   Commentaries on Twitter In a phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants the incidence of serious adverse effects was low and the vaccine efficacy was 74%. Efficacy was documented in a range […]

The post Randomized trial with over 30.000 patients showed AstraZeneca vaccine was safe and resulted in 74% efficacy against symptomatic SARS-CoV-2 infection. appeared first on Links Medicus.